Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the randomized, double-blind, phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback